Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

• Status: Completed
• Trial end date: 2019-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Aim: To study the effectiveness and safety of empagliflozin as a preoperative preparation tool, as well as to improve the long-term prognosis of planned percutaneous coronary interventions in patients with type 2 diabetes

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Research Institute for Complex Problems of Cardiovascular Diseases, Russia
• Treatments: Empagliflozin; Hypoglycemic Agents; Metformin

Criteria

Inclusion Criteria:

• signed inform concent

• stable coronary artery disease

• planned percutaneous coronary intervention

• diabetes mellitus

Exclusion Criteria:

• previously performed coronary revascularization

• glomerular filtration rate less than 45 ml/min

• intolerance to empagliflozin

• serum potassium more than 5/5 mmol/l

• heart failure (NYHA III-IV)

• congenital heart disease

• acute coronary syndrome less than 3 months before enrollment